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Abstract 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not topical 
eflornithine is an effective adjunctive therapy in reducing unwanted facial hair in women 
diagnosed with hirsutism. 
 
STUDY DESIGN: Systematic review of three randomized controlled trials (RCTs) from peer 
reviewed journals, published in 2006, 2007 and 2016. 
 
DATA SOURCES: The studies analyze the effectiveness of eflornithine in women with 
hirsutism and were found using PubMed, Embase and Medline.  
 
OUTCOMES MEASURED: Reduction of unwanted facial hair was measured through hair 
counts done at 0, 1, 3 and 6 months, Physician Global Assessment which considered hair length, 
density and darkening of skin, and Patient Self-Assessment. 
 
RESULTS: Two of the randomized control trials suggested that the addition of topical 
eflornithine was statistically significant in the reduction of unwanted facial hair in women with 
hirsutism. The other study suggested that while eflornithine may initially be beneficial in the 
reduction of unwanted facial hair, it’s utility decreases after 6 months.  
 
CONCLUSIONS: On the basis of hair counts, Physician Global Assessments, and Patient Self-
Assessment, it can be concluded that topical eflornithine is an effective adjunctive therapy in 
reducing unwanted facial hair in women diagnosed with hirsutism for at least the first 6 months. 
 
KEY WORDS: topical eflornithine, hirsutism 
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INTRODUCTION 
 
 As humans, we are covered from head to toe with hair follicles that can stimulate the 
growth of three different types of hair: lanugo, vellus or terminal.  Lanugo is the thin, soft 
unpigmented hair that covers newborns and disappears within the first few months.1  Vellus is 
also soft and unpigmented hair, but it is a little thicker, generally 0.03 mm in diameter.1  
Terminal hairs are longer, coarse pigmented hairs that are at least 0.06 mm in diameter.1  
Hirsutism is defined as excessive terminal hair growth in women, typically in the androgen-
dependent areas of the body such as the upper lip, chin, chest and abdomen.  It is important that 
we distinguish hirsutism from hypertrichosis, which is characterized as generalized or localized 
vellus hair growth in a nonsexual distribution that is independent of androgens.2 
Hirsutism is said to affect anywhere from 7-25% of women in the U.S.2,3 and is 
associated with a decreased quality of life and lower self-esteem.3  Every year, women in the 
U.S. spend billions of dollars on hair removal, which makes finding an exact number specific to 
hirsute women difficult, however, it has been estimated to be over $600 million annually.2  The 
most common cause of hirsutism is polycystic ovarian syndrome (PCOS) which affects roughly 
5 million women of child bearing age.4  It is difficult to pinpoint exactly how many healthcare 
visits are made each year due to hirsutism.  We know that between 2003-2008, there were 
207,662 PCOS-related visits4 and up to 75% of women with PCOS have some degree of 
hirsutism, so we can estimate that up to 155,747 of those visits involved discussions about 
excessive hair growth. 
Different cultures have different opinions about the appropriate amount of body hair, 
which again, makes calculating statistics difficult.  While we know, hirsutism is associated with 
certain disorders such as PCOS, adrenal hyperplasia, thyroid dysfunction etc., it is difficult to 
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detect how many women are living with hirsutism by “our standards” because their cultural 
standards may say their hair distribution is normal.  A proper work up of suspected hirsutism 
should include a history and physical, hormone profile, metabolic profile, ovulatory function 
tests and ultrasound evaluation.3  The gold standard for evaluation would be the modified 
Ferriman-Gallway score (mFG).  The mFG score is calculated during physical examination of 11 
body areas: upper lip, chin, chest, upper and lower back, upper and lower abdomen, arm, 
forearm, thigh, and lower leg.3  Each area is given a score 1 - 4 based on the amount of visible 
terminal hair; 11-15 is considered mild, 16-25 is moderate, and above 25 is severe.  It is crucial 
to continue the extensive evaluation even after noting an androgen excess, because androgen 
excess does not correlate well with the actual severity. 
Eflornithine hydrochloride, brand name Vaniqa, is an antiprotozoal most commonly used 
as a topical but can also be administered intravenously, brand name Priotto.5  The topical works 
by inhibiting ornithine decarboxylase (ODC)5, the enzyme that inhibits cell division and 
synthetic functions, and can thereby affect the rate of hair growth.  It has been proposed that the 
combination of eflornithine with laser treatment is a safe and effective way to further reduce the 
growth and appearance of unwanted facial hair, thereby improving overall quality of life.  This 
paper evaluates three blind, randomized controlled trials (RCTs) comparing the efficacy of 
topical eflornithine as an add on therapy for the reduction of unwanted facial hair.  
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not topical 
eflornithine is an effective adjunctive therapy in reducing unwanted facial hair in women 
diagnosed with hirsutism. 
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METHODS 
 The studies selected for this systematic review included a randomized split-face single 
blinded controlled trial6 and two randomized double-blinded controlled trials7,8.  They were 
selected based on their population, intervention, and comparison.  The population for this review 
includes women over the age of 18 years who have hirsutism.  The intervention is topical 
eflornithine used in conjunction with laser hair therapy.  All the women were treated with some 
form of laser therapy, applied eflornithine cream to one half of their face and either a placebo 
vehicle cream or nothing to the other half of their face.  Right to left comparisons were then 
made by the participants themselves in addition to the physicians leading the study.  Before and 
after hair counts were also used to aid in the comparison process.  
 All three of the articles included were published in peer reviewed journals and found 
using the following databases: PubMed, Embase and Medline.  The articles were chosen using 
the keywords “hirsutism” and “eflornithine” then selected based on their relevance to each other, 
the clinical question and the presence of patient oriented evidence that matters (POEMs).  
Articles were excluded if they were published greater than ten years ago, included pregnant or 
lactating women or were not blinded controlled trials.  Additional inclusion and exclusion 
criteria for each individual article can be found in Table 1, as well as their specific 
demographics.  Each article was published in the English language.  Significance of the results 
was determined through evaluation of the calculated p-value, relative benefit increase (RBI), 
absolute benefit increase (ABI) and number needed to treat (NNT).  Safety of the medication was 
also monitored. 
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Table 1 – Demographics and characteristics of included studies 
Study Type # 
of 
Pts 
Age Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Vissing6 
(2016) 
Single 
blinded 
RCT 
18 26-
46 
>18 years, 
moderate to 
severe facial 
hirsutism 
Pregnant, lactating, 
immunosuppressant 
medication, unable 
to follow protocol 
4 Topical 
eflornithine 
initiated 2 
days after 
IPL (laser)-
treatment 
Applied BID 
x 6 months 
Hamzavi7 
(2007) 
Double 
blind 
RCT 
31 22-
65 
>18 years, 
carried out 
upper lip hair 
removal of 
any kind at 
least twice a 
week, 
predominantly 
dark facial 
hair, willing 
to discontinue 
all hair 
removal 
modalities for 
2 weeks 
before study  
Presence of tattoos 
over or near the 
upper lip, 
photosensitivity, 
severe acne 
vulgaris, pregnancy, 
lactating, 
immunosuppression 
2 Apply thin 
layer of 
eflornithine 
to one half 
of upper lip 
and placebo 
cream to 
other half of 
lip BID in 
addition to 6 
laser 
treatments of 
the entire lip 
at 4 week 
intervals  
Smith8 
(2006) 
Double 
blind 
RCT 
54 26-
80 
Fitzpatrick 
skin types I-
IV, bilaterally 
symmetric 
facial 
hirsutism of 
the lip and 
chin, 
predominantly 
brown/black 
terminal hairs, 
hair density of 
5 hairs/cm2 
Pregnant, lactating, 
recent use of laser 
photoepilation or 
electrolysis, 
systemic 
medications that 
affect hair growth  
10 Apply 
topical 
eflornithine 
on one side 
of face and 
vehicle on 
the 
contralateral 
side for 34 
weeks and 
receive laser 
therapy to 
both sides at 
weeks 2 and 
10 
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OUTCOMES MEASURED 
 The outcome measured in all three studies was the effectiveness of topical eflornithine in 
reducing the amount of unwanted facial hair.  This was measured via hair counts at 0, 1, 3 and 6 
months, Physician Global Assessment and Patient Self-Assessment.  Photographs would be 
taken and digitized to a 1324 x 1024 pixel image7 and all visible hairs would be manually 
counted, right and left sides separately.  The physician global assessment was a 0 – 3 grade scale 
that considered changes in hair length, hair density and darkening of the skin (see Table 2). 
Table – 2 Physician Global Assessment of facial hair response.7,8  
Grade 0 No improvement / worse – no decrease or increased visibility of terminal 
hair and darkening of skin due to terminal hair is worse or not improved 
Grade 1 Improved – clinically apparent decrease in visibility of terminal hair and 
noticeable lightening of facial skin due to terminal hair 
Grade 2 Marked improvement – considerable decrease in visibility of terminal hair 
and minimal darkening of facial skin due to terminal hair 
Grade 3 Clear / almost clear – no or nearly no visible terminal hair or darkening of 
facial skin due to terminal hair 
 
RESULTS 
 In the study conducted by Vissing et al., 32 women were assessed for eligibility, 22 were 
deemed eligible and 18 completed the 6 month protocol.  Of the 22 that were eligible and 
included in the trial, one withdrew, one was lost to follow up and two were excluded due to 
deviation from the treatment protocol.  A sample size of 18 was determined to detect a minimal 
20% difference in hair counts.  Each participant received 5-6 rounds of photoepilation with laser 
and intense pulsed light (IPL) treatments of their face and neck prior to the study.  Two days 
after the final IPL-treatment was considered baseline and this is when the topical eflornithine 
was initiated.  A nurse did the first application and then instructed each woman to apply a thin 
layer over half of their face, either right or left, twice daily, at least 8 hours apart, for 6 months.  
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Assessments were made at baseline, 1, 3, and 6 months and included hair counts, patient 
satisfaction scores (0-10) and patient evaluated efficacy (0-3).  Evaluators were blind to which 
side of the face was being treated, patients however were not blinded to treatment.  
 Based on hair counts, topical eflornithine reduced hair regrowth by 14% after 1 month   
(P = 0.007), 9% after 3 months (P = 0.107) and 17% after 6 months (P = 0.048) with a 95% 
confidence interval (CI).6  RBI was calculated to be 0%, ABI was calculated to be 72% and NNT 
was 2.  This suggests that for every two hirsute women treated with topical eflornithine for six 
months, one more will have a statistically significant reduction in hair regrowth.  Patients’ 
satisfaction was consistently recorded at a moderate level at every visit, with a median of 5/10 at 
months 1 and 3 and 6/10 at month 6.6  Patient evaluated efficacy of eflornithine improved with 
treatment.  At every assessment, there was always more patients favoring eflornithine treatment 
than no treatment.  After 1 month, only three patients saw a significant difference in hair counts 
compared to six patients after six months.6  This study reported topical eflornithine to have a 
17% additive effect on hair reduction compared to no additional treatment.6  Vissing et al. also 
mentions that it is important to note that half of the participants experienced greater than a 17% 
effect.  In the end 72% of participants (13/18) did take benefit from the topical eflornithine 
treatment. 
 In the study conducted by Hamzavi et al., 33 females enrolled but only 31 participated in 
the 26 week study.  One withdrew after experiencing hyperpigmentation after the second 
treatment and one was lost to follow up.  Patients were scheduled to undergo six treatments with 
a long pulsed alexandrite laser at four week intervals while simultaneously using two different 
topical creams twice daily for two weeks after their final laser treatment.  The creams were in 
color coded tubes, one contained the topical eflornithine, while the other was a simple vehicle 
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placebo cream. This allowed both the patients and the investigators to be blinded throughout the 
study. It is important to note that hand washing was mandatory after each application to prevent 
the risk of cross contamination.  Assessments were conducted at baseline, at four week intervals 
in conjunction with the laser treatments and two weeks after the final treatment and involved hair 
counts, patient self-assessments and investigator global assessments.  
 It should be noted that of 31 women who participated in the study, only 19 underwent all 
six laser treatments.7  Five patients did not require the final treatment because hair regrowth was 
not apparent and the other seven missed one of their scheduled appointments along the way.  
Hair counts always favored the eflornithine treated side and were statistically significant 
throughout the study with a maximum difference of 17% seen after the second treatment (p < 
.0001, 95% CI).7  The assessment made two weeks after the final treatment showed hair counts 
on the eflornithine treated side were 7.9% lower than the placebo side (p < .01, 95% CI).  At the 
conclusion of the study 41.9% (13/31) of participants thought the eflornithine cream provided 
better hair reduction while the remaining 58.1% (18/31) of participants thought there was no 
overall difference (p = 0.029).7  Investigators gave a hair removal grade 3 (see Table 2) to 93.5% 
(29/31) of participants on the eflornithine treated side compared to 67.9% (21/31) of participants 
on the vehicle cream side (p = 0.021).7  The following values were calculated using the 
investigator global assessment data: RBI of 38%, ABI of 25.6% and NNT of 4 (see Table 3).  
This suggests that for every four hirsute women treated with topical eflornithine in conjunction 
with their laser therapy, one will see a statistically significant reduction in hair regrowth.  
 In the study conducted by Smith et al., 2 campuses were used, 64 women were enrolled 
and 54 completed the 34-week trial.  Two women voluntarily withdrew, four were lost to follow 
up and four violated protocol.  Participants were given topical eflornithine and a vehicle cream 
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and were instructed to apply each cream to a specific side of their face twice daily for 34 weeks.   
Assessments were made at weeks 2, 6, 10, 16, 22, 28 and 34 using a physician global assessment 
(see Table 2) of changes from baseline, physician comparison of right to left and a subject self-
assessment comparing right to left.  The upper lip area and chin were evaluated separately. After 
evaluations were made at weeks 2 and 10, each patient underwent a laser therapy treatment.   
 Using the physician global assessment, a statistically significant treatment benefit can be 
seen at week 6 (p = 0.007), week 10 (p < 0.001), week 16 (p = 0.015) and week 22 (p < 0.001) 
for the upper lip and at week 6 (p = 0.024), week 10 (p < 0.001) and week 22 (p = 0.48) for the 
chin.8  At the final evaluation, 34 weeks, physician right to left comparison showed preference 
for the eflornithine treated side in 22.2% (12/54) of participants and preference for the vehicle 
treated side in 25.9% (14/54) of participants (p = 0.845).8  The remaining participants did not 
demonstrate a difference between sides at 34 weeks.  RBI was calculated to be <-1%, ABI was 
calculated to be -4% and the NNT was -25 (see Table 3).  This suggests that for every 25 patients 
treated, one less will benefit compared to control.  In their self-assessments, patients consistently 
preferred the eflornithine treated side to the vehicle treated side (p = 0.017). 
 All three studies also closely monitored their participants for adverse events.  In general, 
topical eflornithine was found to tolerated well with no serious or prolonged effects.  Adverse 
events noted included the development of acne, dermatitis, redness, pigmentation, paresthesia 
and reactivation of herpes simplex.6,8  Most events resolved on their own under continued 
eflornithine treatment without the need for medical intervention.  
Table 3 – Efficacy of Eflornithine and statistical significance 
 RBI ABI NNT p-value 
Vissing (2016) 0% 72% 2  0.048 
Hamzavi (2007) 38% 25.6% 4 0.021 
Smith (2006) <-1% -4% -25 0.845 
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DISCUSSION 
 Eflornithine (Vaniqa) is a topical antiprotozoal agent used to reduce unwanted hair in 
women.  The most common adverse reactions associated with the medication are acne vulgaris 
(11-21%) and pseudofolliculitis barbae (5-16%).3  Less likely (<10%) adverse events include 
headaches, tingling skin, dizziness, pruritus, rash, xeroderma, erythema, alopecia, dyspepsia and 
anorexia.3  These reactions are consistent with those identified in all three studies.  There are 
currently no known drug interactions with eflornithine and it is considered to be a pregnancy 
Category C drug.  Information related to its use in pregnant or lactating women is limited, so it is 
best to exercise caution and consult a medical provider before continuing or starting the drug.  
The safety and efficacy of eflornithine has also not been studied in children under 12. 
Vaniqa is the first and only prescription hair reduction cream to be FDA approved.  For a 
45 gram tube the price is roughly $199.203 based on a single manufacturer.  Unfortunately, most 
insurance policies will not cover this prescription leaving its recipients with an expensive bill.  
To help minimize patient costs, the company does offer a rebate program, however it is only 
available for those with private insurance or cash paying customers.  
After analyzing the results of three RCTs, it is important that we discuss their limitations.  
The most glaring issue with the studies conducted by Vissing et al and Hamzavi et al are without 
a doubt their sample sizes, 18 and 31 respectively.  While the population is relatively small, it is 
still expected to have a sample size of at least 50.  Despite some limitations, all three RCTs are 
POEMs meaning they are relevant to the population.  They are also all valid studies.  The 
presence of p-values, confidence intervals, randomization and blinding are all factors that 
attribute to each of the studies validity. 
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CONCLUSION 
The primary objective of this systematic review was to determine whether or not topical 
eflornithine is an effective adjunctive therapy in reducing unwanted facial hair in women 
diagnosed with hirsutism.  Unfortunately, the evidence provided by these RCTs is conflicting so 
we are unable to confidently answer the question.  Two of the studies showed statistically 
significant evidence that supports the effectiveness of eflornithine, however, the third study is 
unable to support its effectiveness.  Smith et al had the largest sample size but they were unable 
to prove that topical eflornithine was an effective adjunctive therapy.  In fact, their data, had it 
been statistically significant, would have proven the exact opposite.  Due to its lack of 
significance, we cannot say for certain that this study counteracts the first two.  
In order to improve future studies, it is important to establish a large sample size that 
would be more reflective of the population.  It would also be interesting to compare groups of 
participants who use the topical eflornithine during their laser hair treatments to those who 
undergo laser hair therapy prior to starting the eflornithine.  I would continue to do the split face 
trials and incorporate a placebo cream so both patient and physician were blind.  I would also 
implement hair counts, physician scores and self-assessments.  Being that this topic is about 
patient oriented evidence that matters, the self-assessment is arguably the most important aspect.  
If hair counts suggest that there is no difference between the placebo and the test cream, but the 
patient believes they see an improvement, they are going to keep using it.  
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